Investors & Media

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 7, 2017-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Sage will participate in a fireside chat presentation at
View HTML
Toggle Summary Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder
– SAGE-217 met primary endpoint and provided rapid, profound and durable effects through 2-week treatment period and additional 4-week follow-up – – Well-tolerated and demonstrated highly statistically significant mean reduction in the HAM-D score compared to placebo at 15 days (p
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 4, 2017-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on December 1, 2017 , the Compensation Committee of Sage’s
View HTML
Toggle Summary Sage Therapeutics Announces Closing of $345 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 17, 2017-- Sage Therapeutics  (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public
View HTML
Toggle Summary Sage Therapeutics Prices Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 14, 2017-- Sage Therapeutics  (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,529,411
View HTML
Toggle Summary Sage Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 13, 2017-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $300.0
View HTML
Toggle Summary Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression
Statistically significant mean reduction in the HAM-D score compared to placebo at 60 hours demonstrated in both trials Brexanolone provided a rapid and durable reduction over 30 days in depressive symptoms as measured by HAM-D in both placebo-controlled multi-center trials Positive results support
View HTML
Toggle Summary Sage Therapeutics Appoints Asha Nayak, M.D., Ph.D., to Board of Directors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2017-- Sage Therapeutics , Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the addition of Asha Nayak , M.D., Ph.D., chief medical
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 3, 2017-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on November 1, 2017 , the Compensation Committee of Sage’s Board
View HTML
Toggle Summary Sage Therapeutics Announces Third Quarter 2017 Financial Results and Provides Pipeline Update
Enrollment completed in both Phase 3 trials of brexanolone in postpartum depression and in the Phase 2 placebo-controlled trial of SAGE-217 in major depressive disorder Activity in open-label Parkinson’s disease trial and essential tremor trial supports further clinical development A Phase 1 single
View HTML